GSK3β-dependent cyclin D1 and cyclin E1 degradation is indispensable for NVP-BEZ235 induced G0/G1 arrest in neuroblastoma cells
- 14 November 2017
- journal article
- research article
- Published by Taylor & Francis in Cell Cycle
- Vol. 16 (24) , 2386-2395
Abstract
Cyclin D1 and cyclin E1, as vital regulatory factors of G1-S phase cell cycle progression, are frequently constitutive expressed and associated with pathogenesis and tumorigenesis in most human cancers and they have been regarded as promising targets for cancer therapy. In this study, we established NVP-BEZ235, a potent dual kinase inhibitor, could induce neuroblastoma cells proliferation inhibition without apoptosis activation. Moreover, we showed NVP-BEZ235 could induce neuroblastoma cells arrested at G0/G1 phase accompanied with significant reduction of the cyclin D1 and E1 proteins in a dose dependent manner at nanomole concentration. Additionally we found that GSK3β was dephosphorylated and activated by NVP-BEZ235 and then triggered cyclin D1 and cyclin E1 degradation through ubiquitination proteasome pathway, based on the evidences that NVP-BEZ235 induced downregulation of cyclin D1 and cyclin E1 were obviously recovered by proteasome inhibitor and the blockade of GSK3β contributed to remarkable rescue of cyclin D1 and cyclin E1. Analogous results about its anti-proliferation effects and molecular mechanism were observed on neuroblastoma xenograft mouse model in vivo. Therefore, these results indicate that NVP-BEZ235-induced cyclin D1 and cyclin E1 degradation, which happened through activating GSK3β, and GSK3β-dependent down-regulation of cyclin D1 and cyclin E1 should be available for anticancer therapeutics.Keywords
Funding Information
- National Natural Science Foundation of China (81172322, 81302006)
- Shanghai Municipal Education Committee (13ZZ089)
- Science and Technology Committee of Shanghai (14401901500, 12-E-2)
- NO.3 People's Hospital affiliated to Shanghai Jiao-Tong University School of Medicine (sy2013-008)
This publication has 36 references indexed in Scilit:
- Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survivalCell Death & Disease, 2017
- Oridonin enhances the anticancer activity of NVP-BEZ235 against neuroblastoma cells in vitro and in vivo through autophagyInternational Journal of Oncology, 2016
- Damnacanthal and its nanoformulation exhibit anti-cancer activity via cyclin D1 down-regulationLife Sciences, 2016
- Metformin induces degradation of cyclin D1 via AMPK/GSK3β axis in ovarian cancerMolecular Carcinogenesis, 2016
- The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphomaLeukemia, 2010
- Cyclin D1 Degradation Is Sufficient to Induce G1 Cell Cycle Arrest despite Constitutive Expression of Cyclin E2 in Ovarian Cancer CellsCancer Research, 2009
- Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenograftsBritish Journal of Cancer, 2009
- The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic inventionMolecular Cancer, 2007
- PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancerOncogene, 2006
- AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growthOncogene, 2004